Biotech News

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals (ADIL)Adial Pharmaceuticals2024-06-05 08:30 ESTClinical readout

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studies and support ongoing partnership discussions

Topline results expected in early Q4 2024

GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close: 4.80 USD
Market cap: 5.06M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States